FOXO TECHNOLOGIES INC.

FOXO Technologies Inc. (NYSE American: FOXO) completed its de-SPAC merger in September 2022 through a business combination with CF Acquisition Corp. VIII, a blank-check company sponsored by Cantor Fitzgerald. The transaction brought FOXO—a Minneapolis-based insurtech company applying epigenetic biomarker science to life insurance underwriting—into the public markets. FOXO's platform uses DNA methylation data to assess longevity and mortality risk, positioning the company at the intersection of biotechnology and financial services. The Form 425 filing dated September 9, 2022, was submitted in connection with communications related to that pending combination. Readers seeking the full deal timeline, filing history, and comparable transactions can access comprehensive data by signing up at SpacDesk.